Key Takeaways
- Shane Sheets, director of the Midwest Medical Examiner’s Office in Ramsey, oversees roughly 1,200 autopsies and an equivalent number of toxicology samples each year.
- Currently, forensic toxicology samples are sent to an out‑of‑state lab in Pennsylvania, with results taking up to six weeks.
- The Randox Evidence Multistat device can analyze a sub‑milliliter blood sample in about 30 minutes, providing preliminary positives for over 24 drug classes on‑site.
- Sheets plans to purchase two or three units at roughly $58,000 each and is seeking a $1.5 million U.S. Department of Justice grant to cover the cost.
- Rapid in‑house results would accelerate law‑enforcement investigations and enable public‑health officials to issue timely alerts about emerging opioid trends, such as spikes in fentanyl or new synthetic opioids.
- Confirmatory testing by the Pennsylvania lab would still be required for court‑admissible evidence, but the device would serve as a powerful screening tool.
- Anoka County recorded 59 fatal drug overdoses in 2025, with fentanyl present in 30 cases; officials stress that even trace amounts can be lethal.
- Sheets’ personal motivation stems from family losses to methamphetamine abuse and an overdose‑related death of his wife’s brother, driving his commitment to reduce the “waiting game” for families seeking answers.
- If funded, the grant decision is expected by September, and the new technology could transform how the medical examiner’s office serves both criminal justice and community health needs.
Overview of the Medical Examiner’s Caseload
Shane Sheets leads the Midwest Medical Examiner’s Office in Ramsey, where his team handles a substantial workload. Annually, they conduct approximately 1,200 autopsies and manage a comparable volume of forensic toxicology samples. These specimens are screened postmortem for drugs, alcohol, and other substances that may have contributed to a death. The sheer number of cases creates a constant demand for timely, accurate toxicology data, both for legal proceedings and for public‑health surveillance.
Current Laboratory Workflow and Delays
At present, the office forwards all toxicology samples to an external laboratory located in Pennsylvania. The shipping, preparation, and analysis process can stretch results out to as long as six weeks. This lag creates a bottleneck: law‑enforcement investigators wait weeks before they can confirm whether a controlled substance played a role in a death, and public‑health officials lack real‑time insight into drug‑use trends that could inform prevention efforts. The delay also prolongs the anguish of families awaiting answers about their loved ones’ cause of death.
Introduction of the Randox Evidence Multistat
Sheets sees a solution in the Randox Evidence Multistat, a compact analytical platform capable of determining the chemical composition of a blood sample in roughly 30 minutes. The device requires less than a millimeter of blood; the sample is inserted, and the instrument screens for more than 24 different drug classes, delivering a preliminary positive or negative readout almost instantly. While the Multistat does not replace confirmatory testing, its speed offers a powerful front‑line screening tool that can be deployed directly within the medical examiner’s office.
Cost, Quantity, and Funding Strategy
Each Randox Evidence Multistat unit carries a price tag of about $58,000. Sheets envisions acquiring two or three instruments to ensure redundancy and to accommodate the office’s sample throughput. To finance the purchase, he has submitted a grant application to the U.S. Department of Justice requesting $1.5 million. The grant would cover the hardware, installation, training, and any necessary software integration. Sheets expects to learn the outcome of the application by September, a timeline that aligns with the office’s budgeting cycle.
Accelerating Law‑Enforcement Investigations
Rapid toxicology screening would markedly shorten the interval between a death and the availability of actionable data for detectives. Preliminary results from the Multistat could guide investigators toward specific substances, helping them prioritize evidence collection, interview witnesses, and pursue leads while the case is still fresh. Although final court admissibility would still require confirmation by the Pennsylvania lab, the early information could prevent investigative dead ends and reduce the resources spent on fruitless avenues.
Public‑Health Surveillance and Community Alerts
Beyond criminal justice, the device would serve as an early‑warning system for public‑health agencies. Patti Constant, Anoka County’s opioid prevention specialist, notes that the ability to detect spikes in fentanyl or the emergence of novel synthetic opioids within minutes would enable health officials to issue timely alerts. Such notifications could urge the public to test their drugs, encourage harm‑reduction outreach, and inform hospitals to stock appropriate antidotes like naloxone. In a landscape where fentanyl can be lethal in amounts comparable to the tip of a pencil, real‑time data is invaluable for preventing further overdose deaths.
Personal Motivation Driving the Initiative
Sheets’ push for in‑house toxicology is not purely professional; it is deeply personal. He reveals that both his brother and his father have long‑standing histories of methamphetamine abuse, and his wife’s family lost a brother to an overdose. These experiences have left him acutely aware of the anguish families endure while waiting for toxicology results. By shortening that wait, Sheets hopes to spare other families the prolonged uncertainty that he has witnessed firsthand, turning a professional upgrade into a compassionate response to his own lived experience.
Confirmatory Testing and Legal Standards
While the Randox Evidence Multistat provides swift screening, Sheets emphasizes that any result intended for use in a criminal investigation or courtroom must be verified by a certified laboratory—currently the Pennsylvania facility. The Multistat’s output would be treated as a presumptive finding, prompting the confirmatory analysis required for evidentiary standards. This two‑step approach balances the need for speed with the rigor demanded by the justice system, ensuring that rapid screening does not compromise the integrity of legal proceedings.
Broader Implications for Anoka County and Beyond
If the grant is successful and the devices are deployed, Anoka County could become a model for other medical examiner offices grappling with similar delays. The ability to produce near‑real‑time toxicology data would not only aid individual cases but also enrich regional drug‑surveillance networks, offering policymakers timely insights into substance‑use trends. Ultimately, the initiative seeks to marry technological efficiency with public‑health vigilance, aiming to reduce overdose fatalities and provide swifter closure for bereaved families.